GU Cancers 2024 | Elucidating the biology of upper tract urothelial cancer

Bishoy Faltas, MD, Weill Cornell Medicine, New York, NY, discusses research on the characterization of upper tract urothelial cancer (UTUC). Most cases of UTUC are luminal-papillary, have an immunodepleted contexture, and have high FGFR3 expression, making it unique to other cases of bladder cancer. The findings provide context to multiple trials such as the THOR trial (NCT03390504), where patients with UTUC who have the aforementioned characteristics tend to fare worse with the investigatory agent. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.